Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Clin Breast Cancer. 2019 Dec;19(6):450-455. doi: 10.1016/j.clbc.2019.05.012. Epub 2019 Jun 13.
Triple-negative breast cancer (TNBC), which lacks endocrine therapies and targeted therapies, has the worst prognosis of all breast cancers which remain the most common malignancy in women worldwide. Targeting protein for xenopus kinesin-like protein 2 (TPX2) is a microtubule-associated protein that is strongly correlated with chromosomal instability, resulting in the development of different human tumors. Herein, we investigated the relationship between the clinical outcome of TNBC and the expression level of the TPX2 protein.
Patients initially treated at Tongji Hospital for confirmed TNBC were evaluated by immunohistochemical staining and retrospectively recruited into our study. The immunohistochemical staining evaluation of TPX2 was based on the staining intensity and extent. STATA was used to analyze all the data.
In total, 97 patients with TNBC were recruited into our study. The TPX2 protein was overexpressed in almost all patients with TNBC. Our study demonstrated that an elevated TPX2 protein level was significantly associated with worse outcomes in the patients with TNBC, including worse progression-free survival (PFS) and overall survival (OS) (log-rank test, P < .001). Our model also indicated that TPX2 expression was an independent predictor of OS (hazard ratio, 2.20; 95% confidence interval, 1.13-4.28; P = .020) but not of PFS (P = .639).
In conclusion, we demonstrated that TPX2 could be a novel prognostic marker of PFS and OS after the initial treatment of TNBC. We also revealed that TPX2 expression could serve as an independent predictor of OS but not of PFS and a promising therapeutic target in patients with TNBC.
三阴性乳腺癌（TNBC）缺乏内分泌治疗和靶向治疗，是所有乳腺癌中预后最差的，而乳腺癌仍然是全世界女性中最常见的恶性肿瘤。靶向蛋白 for xenopus kinesin-like protein 2（TPX2）是一种微管相关蛋白，与染色体不稳定性强烈相关，导致不同的人类肿瘤的发生。在此，我们研究了 TNBC 的临床结果与 TPX2 蛋白表达水平之间的关系。
我们通过免疫组织化学染色对最初在同济医院接受治疗的确诊为 TNBC 的患者进行评估，并通过回顾性研究将其纳入本研究。TPX2 的免疫组织化学染色评估基于染色强度和范围。使用 STATA 分析所有数据。
我们共纳入了 97 名 TNBC 患者。在几乎所有 TNBC 患者中，TPX2 蛋白都过度表达。我们的研究表明，TPX2 蛋白水平升高与 TNBC 患者的预后不良显著相关，包括无进展生存期（PFS）和总生存期（OS）更差（对数秩检验，P <.001）。我们的模型还表明，TPX2 表达是 OS 的独立预测因子（风险比，2.20；95%置信区间，1.13-4.28；P =.020），但不是 PFS 的预测因子（P =.639）。
总之，我们证明了 TPX2 可能是 TNBC 初始治疗后 PFS 和 OS 的新的预后标志物。我们还揭示了 TPX2 表达可以作为 OS 的独立预测因子，但不是 PFS 的预测因子，并且是 TNBC 患者有希望的治疗靶点。
